TRVI Similar Chart Price Prediction
The price of TRVI is predicted to go up 1.51%, based on the high correlation periods with FI. The similarity of these two price pattern on the periods is 95.23%.
TRVI
FI
Up: 1.51%Similarity: 95.23%
TRVI Revenue Forecast
TRVI EPS Forecast
TRVI FAQs
What is bull’s view on TRVI?
What is bear's view on TRVI?
What is TRVI eps forecast for next quarter？
TRVI Analyst's Forecast
Serge Belanger
Needham
Strong Buy
2024-12-12
Price Target
$8
Upside
+122.22%
Needham analyst Serge Belanger says Trevi Therapeutics' Phase 2b CORAL trial evaluating Haduvio for idiopathic pulmonary fibrosis cough underwent a successful sample-size re-estimation analysis which determined the study could continue with no changes to the originally-planned sample size. This is the "best case outcome" of the trial's analysis given that the study could have been halted due to futility or required additional patients, the analyst tells investors in a research note. The firm says there are two takeaways for this outcome, both of which are "de-risking" for the trial readout: the treatment effect size and study dropouts are in-line with original statistical powering assumptions. It keeps a Buy rating on Trevi with an $8 price target. The stock in midday trading is up 70%, or $1.75, to $4.24.
